These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. Popović I, Ravanić D, Popović V, Vladejić S, Stanojević A, Stojanović M. Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740 [Abstract] [Full Text] [Related]
4. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH. J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371 [Abstract] [Full Text] [Related]
5. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268 [Abstract] [Full Text] [Related]
6. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, El Tallawy H, Danaci AE, Lowe W, Karayal ON. Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959 [Abstract] [Full Text] [Related]
7. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Conley RR, Mahmoud R. Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400 [Abstract] [Full Text] [Related]
8. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207 [Abstract] [Full Text] [Related]
10. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I, IC-SOHO Study Group. J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069 [Abstract] [Full Text] [Related]
11. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA. J Clin Psychiatry; 2004 Jan; 65(1):57-61. PubMed ID: 14744169 [Abstract] [Full Text] [Related]
12. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha S, Ameen S, Akhtar S. J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337 [Abstract] [Full Text] [Related]
13. Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. Peuskens J, Gillain B, De Graeve D, Van Vleymen B, Albert A. Eur Psychiatry; 2009 Apr; 24(3):154-63. PubMed ID: 19118983 [Abstract] [Full Text] [Related]
17. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, Buchkremer G, Heuser I, Klosterkötter J, Gastpar M, Braus DF, Schlösser R, Schneider F, Ohmann C, Riesbeck M, Gaebel W. Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670 [Abstract] [Full Text] [Related]
19. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. István S, Agoston T, Tamás T, Zoltán J. Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029 [Abstract] [Full Text] [Related]